Christopher Browning
GlaxoSmithKline
5 Papers
29 Citations
Christopher Browning is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Histamine & Chemistry. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors
Robert J. Slack,Linda J. Russell,David A. Hall,Mark A. Luttmann,Alison J. Ford,KA Saunders,Simon Teanby Hodgson,HE Connor,Christopher Browning,Kenneth L. Clark +9 more
TL;DR: Preclinical pharmacological characterization of GSK1004723, a novel, dual histamine H1 and H3 receptor antagonist, is presented.
4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H3 Receptor Antagonists
Panayiotis A. Procopiou,Rachael A. Ancliff,Mark James Bamford,Christopher Browning,Helen E. Connor,Susannah Davies,Fogden Yvonne C,Simon Teanby Hodgson,Duncan S. Holmes,Brian Edgar Looker,Karen M. L. Morriss,Christopher A. Parr,Elizabeth Pickup,Sanjeet Singh Sehmi,Gemma Victoria White,Clarissa J. Watts,David Matthew Wilson,Woodrow Michael David +17 more
TL;DR: A series of ketopiperazines were prepared and evaluated for their activity as histamine H 3 antagonists and compound 22i was identified as the best compound based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties.
26
Oxazolidinones as novel human CCR8 antagonists.
Jian Jin,Yonghui Wang,Feng Wang,Jeffery K. Kerns,Victoria Vinader,Ashley Paul Hancock,Matthew J Lindon,Graeme Irvine Stevenson,Dwight M. Morrow,Parvathi Rao,Cuc Nguyen,Victoria J. Barrett,Christopher Browning,Guido Hartmann,David P. Andrew,Henry M. Sarau,James J. Foley,Anthony J. Jurewicz,James A. Fornwald,Andy J. Harker,Michael L. Moore,Ralph A. Rivero,Kristen E. Belmonte,Helen E. Connor +23 more
TL;DR: The synthesis, structure-activity relationships, and optimization of the series of N-substituted-5-aryl-oxazolidinones that led to the identification of SB-649701 (1a) are described.
20
Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.
Panayiotis A. Procopiou,Christopher Browning,Paul Martin Gore,Sean M. Lynn,Stephen A. Richards,Robert J. Slack,Steven L. Sollis +6 more
TL;DR: The more potent and selective 6-azaphthalazinone core was used to append an H(3) receptor antagonist fragment, and to convert the series into the long acting single-ligand, dual H(1) H( 3) receptor receptor antagonist 44.
11
The Discovery of Phthalazinone-Based Human H1 and H3 Single-Ligand Antagonists Suitable for Intranasal Administration for the Treatment of Allergic Rhinitis
Panayiotis A. Procopiou,Christopher Browning,Jennifer M. Buckley,Kenneth L. Clark,Lise C. Fechner,Paul Martin Gore,Ashley Paul Hancock,Simon Teanby Hodgson,Duncan S. Holmes,Michael Kranz,Brian Edgar Looker,Karen M. L. Morriss,Daniel L. Parton,Linda J. Russell,Robert J. Slack,Steven L. Sollis,Sadie Vile,Clarissa J. Watts +17 more
TL;DR: Compound 56a had longer duration of action than azelastine, low brain penetration, and low oral bioavailability, which coupled with the predicted low clinical dose should limit the potential of engaging CNS-related side-effects associated with H(1) or H(3) antagonism.